MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

Search

Corcept Therapeutics Inc

Abierto

SectorSanidad

95.63 -12.74

Resumen

Variación precio

24h

Actual

Mínimo

91.4

Máximo

116.77

Métricas clave

By Trading Economics

Ingresos

-16M

31M

Ventas

-656K

182M

P/B

Media del Sector

48.35

73.239

BPA

0.26

Margen de beneficios

16.904

Empleados

500

EBITDA

-21M

26M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+9.09% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-737M

6.3B

Apertura anterior

108.37

Cierre anterior

95.63

Noticias sobre sentimiento de mercado

By Acuity

15%

85%

18 / 386 Clasificación en Healthcare

Corcept Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2025, 22:45 UTC

Principales Noticias

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 mar 2025, 23:54 UTC

Charlas de Mercado

Nikkei May Rise After Monday's Selloff -- Market Talk

31 mar 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 mar 2025, 23:15 UTC

Charlas de Mercado

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 mar 2025, 23:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

31 mar 2025, 22:33 UTC

Principales Noticias

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 mar 2025, 22:28 UTC

Ganancias

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke Swings to Loss for 2024 >000002.SZ

31 mar 2025, 21:47 UTC

Principales Noticias

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 mar 2025, 21:44 UTC

Principales Noticias

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 mar 2025, 21:21 UTC

Charlas de Mercado

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 mar 2025, 21:18 UTC

Principales Noticias

Copper Is 2025's Hottest Commodity -- Update

31 mar 2025, 21:09 UTC

Principales Noticias

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 mar 2025, 21:02 UTC

Ganancias

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 mar 2025, 21:01 UTC

Ganancias

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 mar 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

31 mar 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 mar 2025, 20:37 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 mar 2025, 20:17 UTC

Principales Noticias

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 mar 2025, 20:13 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 mar 2025, 20:03 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 mar 2025, 19:09 UTC

Charlas de Mercado

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 mar 2025, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 mar 2025, 18:54 UTC

Charlas de Mercado

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 mar 2025, 18:40 UTC

Charlas de Mercado

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 mar 2025, 18:34 UTC

Charlas de Mercado

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 mar 2025, 18:28 UTC

Charlas de Mercado

Gold Climbs to Close Out Quarter -- Market Talk

31 mar 2025, 18:03 UTC

Principales Noticias

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Comparación entre iguales

Cambio de precio

Corcept Therapeutics Inc previsión

Precio Objetivo

By TipRanks

9.09% repunte

Estimación a 12 Meses

Media 124.6 USD  9.09%

Máximo 150 USD

Mínimo 78 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corcept Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

18 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.